Epcoritamab
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Epcoritamab, sold under the brand name Epkinly among others, is a Bi-specific T-cell engager (BiTE) used for the treatment of diffuse large B-cell lymphoma. Epcoritamab is a bispecific CD20-directed CD3 T-cell engager. Epcoritamab was co-developed by AbbVie and Genmab. Epcoritamab was approved for medical use in the United States in May 2023, in the European Union in September 2023, and in Canada in December 2023.
Epcoritamab, sold under the brand name Epkinly among others, is a Bi-specific T-cell engager (BiTE) used for the treatment of diffuse large B-cell lymphoma. Epcoritamab is a bispecific CD20-directed CD3 T-cell engager. Epcoritamab was co-developed by AbbVie and Genmab. Epcoritamab was approved for medical use in the United States in May 2023, in the European Union in September 2023, and in Canada in December 2023.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1372906024 under CC BY-SA 4.0; modifications have been made.